Citi analyst Geoff Meacham lowered the firm’s price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces analyses from Phase 3 C-Post trial
- Regeneron: Buy Rating Reaffirmed Amid Growth Prospects and Attractive Valuation
- Regeneron price target lowered to $645 from $686 at Leerink
- Regeneron downgraded at RBC Capital after ‘disappointing’ itepekimab results
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue